|
Correction
The July 16 issue of Washington Drug Letter contained incorrect information regarding the FDA’s statements about compounded versions of KV Pharmaceuticals pre-term birth drug Makena (hydroxyprogesterone caproate). The FDA said on June 29 it may take enforcement action against compounding pharmacies producing copies of the drug.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives